Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population

Diabetes Research and Clinical Practice
Yoshiharu TokuyamaAzuma Kanatsuka

Abstract

To address the possibility that the partial disruption of Glucagon-like peptide-1 (GLP-1) signaling could cause diabetes, we tried to detect the mutation in GLP-1 receptor (GLP-1R) gene in the population with type 2 diabetes. Genomic DNA was extracted from 36 unrelated Japanese type 2 diabetic subjects and directly sequenced for the GLP-1R gene. For the detected polymorphisms, 791 patients with type 2 diabetes and 318 controls were screened by polymerase chain reaction-restricted fragment length polymorphism and association study was carried out. Five missense and four silent variants were detected in the GLP-1R gene. There were no significant differences in the frequencies of Pro7Leu, Arg44His and Leu260Pro polymorphism between the diabetic and control groups. And also there were no significant differences in body mass index (BMI), onset age and fasting IRI among the wild type, heterozygote and homozygote of these variants in diabetic patients. Thr149Met mutation was detected in one case among 791 type 2 diabetes patients, but not in control subjects. The patient with this mutation exhibited impairment of both insulin secretion, insulin sensitivity and glucose effectiveness, which may be partially explained by Thr149Met mutati...Continue Reading

References

Jul 1, 1992·Diabetes/metabolism Reviews·W Creutzfeldt, M Nauck
Sep 1, 1980·The Journal of Clinical Endocrinology and Metabolism·R P EatonJ Standefer
Jun 25, 1996·Biochemical and Biophysical Research Communications·R S HellerJ F Habener
Jan 30, 2002·Diabetes Care·Zachary T Bloomgarden

❮ Previous
Next ❯

Citations

Apr 12, 2008·World Journal of Pediatrics : WJP·Bao-Sheng Yu, An-Ru Wang
Sep 29, 2012·Molecular Diagnosis & Therapy·Gaia Chiara Mannino, Giorgio Sesti
Jun 5, 2012·Pharmacology & Therapeutics·Young Min ChoTimothy J Kieffer
Feb 20, 2007·Pharmacology & Therapeutics·Máire E Doyle, Josephine M Egan
Aug 23, 2005·Diabetes/metabolism Research and Reviews
Apr 19, 2005·Obesity Research·Louis PérusseClaude Bouchard
Dec 3, 2014·Biochemical Pharmacology·Aiysha Thompson, Venkateswarlu Kanamarlapudi
Sep 2, 2010·Diabetes Care·Michael A Nauck, Irfan Vardarli
May 12, 2016·Pharmacogenomics·Ivan Tkáč, Ivana Gotthardová
Jul 27, 2017·The Journal of Gene Medicine·Sally M ShalabyRehab H El-Sokkary
Dec 6, 2018·Diabetes/metabolism Research and Reviews·Gaia Chiara ManninoGiorgio Sesti
Mar 26, 2014·Endocrine Reviews·Ya-Xiong Tao, P Michael Conn
Nov 10, 2005·Journal of Endocrinological Investigation·C M RotellaE Mannucci
Aug 26, 2019·Journal of Molecular Biology·Alejandra TomasColin Leech
Aug 27, 2021·Expert Opinion on Pharmacotherapy·Muhammad Abdul-Ghani, Ralph A DeFronzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.